Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

556
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiopharmaceutical Therapy Meets Radiobiology: Implications for Trial Design and DNA Repair Inhibitor Combinations.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.

Oncoimmunology·2025
Same author

Methodology for comparing absorbed dose rate calculation algorithms in molecular radiotherapy dosimetry.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2025
Same author

MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same author

Development of an in vivo ovarian cancer peritoneal carcinomatosis model for radioimmunotherapy testing.

Methods in cell biology·2025
Same author

Optical (Cherenkov) dosimetry to unravel the radiobiological effects of radioisotope based therapy.

European journal of nuclear medicine and molecular imaging·2025

Related Experiment Video

Updated: Jul 18, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.5K

Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors.

Jean-Pierre Pouget1, Timothy A Chan2, Lorenzo Galluzzi3

  • 1Institut de Recherche en Cancérologie de Montpellier (IRCM), Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France.

Trends in Cancer
|August 23, 2023
PubMed
Summary

Targeted radionuclide therapy (TRT) shows promise for enhancing cancer treatment when combined with immune checkpoint inhibitors (ICIs). This combination may improve patient response rates to immunotherapy, expanding treatment options.

Keywords:
external beam radiation therapyimmune checkpoint inhibitorsimmunogenic cell deathinflammationnivolumabpembrolizumab

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.8K

Related Experiment Videos

Last Updated: Jul 18, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.5K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.8K

Area of Science:

  • Oncology
  • Immunotherapy
  • Radiopharmaceutical Therapy

Background:

  • Immune checkpoint inhibitors (ICIs) have transformed cancer care but benefit only a subset of patients.
  • Developing effective combination therapies is crucial to broaden ICI efficacy.
  • Targeted radionuclide therapy (TRT) offers potential immunostimulatory effects and a favorable safety profile.

Purpose of the Study:

  • To explore the potential of targeted radionuclide therapy (TRT) as a combinatorial partner for immune checkpoint inhibitors (ICIs).
  • To review preclinical and clinical evidence supporting TRT/ICI combinations.

Main Methods:

  • Review of preclinical cancer models investigating TRT and ICI combinations.
  • Analysis of clinical findings on TRT and ICI efficacy and safety.

Main Results:

  • TRT exhibits immunostimulatory effects in preclinical settings.
  • TRT demonstrates a good safety and efficacy profile.
  • Preclinical and clinical data suggest TRT is a viable partner for ICI combinations.

Conclusions:

  • Targeted radionuclide therapy (TRT) is a promising strategy for combination with immune checkpoint inhibitors (ICIs).
  • TRT/ICI combinations offer a potential platform to enhance cancer treatment and patient outcomes.